VANCOUVER, British Columbia, May 21, 2026 – NervGen Pharma Corp. (NASDAQ: NGEN) announced today the pricing of an underwritten public offering that will generate gross proceeds of US$60.0 million. The offering consists of 24,000,000 common shares and accompanying warrants to purchase up to an additional 24,000,000 common shares.
Offering Details
The common shares are being offered at a public offering price of US$2.50 per share. Each accompanying warrant carries an exercise price of US$3.68 per common share and will be immediately exercisable upon issuance. These warrants will expire five years from the date of issuance.
Company Focus
NervGen Pharma is a clinical-stage biopharmaceutical company dedicated to developing first-in-class neuroreparative therapeutics. The company’s pipeline targets spinal cord injury, as well as other neurotraumatic and neurologic conditions.
The capital raised from this offering is expected to support NervGen’s ongoing clinical development programs and general corporate purposes, bolstering its efforts to bring novel treatments to patients with debilitating neurological disorders.
